Pathologic Complete Response May Be Strong Surrogate Endpoint for Breast Cancer Survival

Pathological complete response appeared to be a viable surrogate outcome for EFS and distant RFS, according to long-term efficacy results from the I-SPY2 TRIAL. 

“Many neoadjuvant trials have established a relationship between pathologic complete response and EFS,” said Dr. Douglas Yee, Departments of Medicine and Pharmacology. 

Read More

Share this post

Related News

  • Couple Returns to Minnesota, This Time to Make an Impact in Medicine

    Rahel Nardos, MD, MCR, and Damien Fair, PA-C, PhD, a married faculty duo are joining the University of Minnesota Medical School in different fields of medicine.Dr. Fair serves as the co-director of the Masonic Institute for the Developing Brain, and Dr. Nardos is an associate professor in the Department of Obstetrics, Gynecology and Women’s Health and serves as a urogynecologist and director for Global Women's Health at the Center for Global Health and Social Responsibility.

  • Long-standing ‘Hand Skills Day’ Simulation Goes Virtual

    With reduced exposure to the operating room during the COVID-19 pandemic, simulated orthopedic training has helped fill in learning gaps for residents, including the department’s James House, MD, Hand Skills Lectureship and Educational Workshop.